Vitamin B12 for Anemia and Hematology

Pernicious anemia was the first disease for which B12 was identified as the cure — it earned the Nobel Prize in Medicine in 1934. Before B12 was characterized, pernicious anemia was uniformly fatal: a relentless progression of fatigue, neurological deterioration, and death over 1-3 years. Today it remains the most well-known clinical context for B12 therapy, but the picture is wider than autoimmune intrinsic factor deficiency alone: megaloblastic anemia from any cause (vegan diet, malabsorption, drug-induced) responds to B12. This deep-dive walks through the molecular mechanism of the megaloblastic defect, the autoimmune pathophysiology of pernicious anemia, the historical Schilling test and its modern replacements, the IM injection protocols, and the surprising clinical reality that high-dose oral B12 works even in pernicious anemia.

Table of Contents

  1. Megaloblastic Anemia Mechanism
  2. Pernicious Anemia
  3. Schilling Test and Its Replacements
  4. Modern Diagnostic Workup
  5. IM Injection Protocols
  6. High-Dose Oral (Berlin Protocol)
  7. Response Monitoring
  8. Combined Iron + B12 + Folate Deficiency
  9. Cautions
  10. Key Research Papers
  11. Connections

Megaloblastic Anemia Mechanism

Megaloblastic anemia is defined by abnormally large, immature red blood cell precursors in the bone marrow (megaloblasts) and abnormally large mature red blood cells in the peripheral blood (macrocytes, or more specifically macro-ovalocytes). The mean corpuscular volume (MCV) is elevated, typically above 100 fL and often above 110 fL in severe cases.

The underlying defect is impaired DNA synthesis in rapidly dividing cells. Erythroblasts in the bone marrow are among the fastest-dividing cells in the body — producing roughly 200 billion new red blood cells every day in a healthy adult. This proliferative burst requires intact synthesis of thymidine, one of the four nucleotide building blocks of DNA. Thymidine is made by the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) by the enzyme thymidylate synthase, which uses 5,10-methylenetetrahydrofolate as its methyl donor.

Here is where B12 enters the picture. The body's largest pool of folate is in the form of 5-methyltetrahydrofolate (5-MTHF). To enter the thymidine synthesis pathway, 5-MTHF must first donate its methyl group to homocysteine via the methionine synthase reaction, regenerating tetrahydrofolate (THF), which can then be reconverted to 5,10-methylenetetrahydrofolate for thymidine synthesis. Methionine synthase requires B12. When B12 is deficient, 5-MTHF cannot donate its methyl group, folate becomes trapped in the methylated form (the "methyl trap"), and the active folate pool needed for thymidine synthesis collapses.

The consequence: erythroblasts cannot synthesize enough thymidine to replicate their DNA. They continue to grow and accumulate cytoplasmic contents (including hemoglobin), but their nuclei lag behind. The result is a giant cell with abundant cytoplasm and an immature, oversized nucleus — the megaloblast. Many of these cells die in the bone marrow (ineffective erythropoiesis); those that mature into circulating red blood cells are oversized, oval-shaped, and short-lived. The patient becomes profoundly anemic despite a hyperactive bone marrow.

Because the defect is upstream of all three blood-cell lineages, severe B12 deficiency can also produce leukopenia (low white blood cells), thrombocytopenia (low platelets), and ultimately pancytopenia (low everything). White blood cells show the same nuclear immaturity defect — hypersegmented neutrophils (5 or more nuclear lobes) are an early and sensitive sign of the megaloblastic process, often present before MCV elevation becomes obvious.

Folate deficiency produces an identical hematological picture through a different mechanism (depletion of folate substrate). This is why supplementing folate alone can correct the anemia of B12 deficiency — folate bypasses the methyl trap by providing fresh folate substrate downstream. The danger: folate supplementation corrects the blood picture but does not fix the methylation defect, so neurological damage continues to progress silently while the patient and clinician think the problem is resolved. This is one of the most important principles in B12 medicine and the reason every patient with macrocytic anemia must have both B12 and folate measured before folate supplementation is started.

Back to Table of Contents

Pernicious Anemia

Pernicious anemia (PA) is the classic and most studied cause of B12 deficiency. It is an autoimmune disease in which the immune system attacks the gastric parietal cells (the cells of the stomach that produce intrinsic factor and stomach acid) or intrinsic factor itself. Two antibody types are characteristic:

Two clinical sub-types of anti-IF antibody exist: type I (blocks B12 binding to IF) and type II (blocks the IF-B12 complex from binding to its ileal receptor). Either pattern produces the same clinical result: B12 cannot be absorbed through the normal physiological pathway, and over years to decades the patient's hepatic B12 stores deplete, leading to the classic triad of macrocytic anemia + neurological symptoms + glossitis.

PA is strongly associated with other autoimmune conditions, particularly:

The "polyglandular autoimmune syndrome" clusters explain why a patient with one autoimmune disease should be screened for B12 deficiency periodically, and why a patient with newly diagnosed pernicious anemia should have thyroid function, fasting glucose, and adrenal function checked.

PA also carries a significantly elevated risk of gastric cancer (approximately 2-3 fold), related to the chronic atrophic gastritis that develops from autoimmune parietal cell destruction. Endoscopic surveillance every 3-5 years is recommended in established PA, particularly if the diagnosis was made before age 50.

Treatment is lifelong B12 supplementation — the underlying autoimmune disease does not remit, and the intrinsic factor deficiency does not reverse. Without sustained B12 replacement, the anemia and neurological complications return inexorably.

Back to Table of Contents

Schilling Test and Its Replacements

The Schilling test was the gold standard for diagnosing B12 absorption defects from the 1950s through the early 2000s. It involved giving the patient an oral dose of radioactive cyanocobalamin (cobalt-57 or cobalt-58 labeled), followed by a large parenteral "flushing" dose of unlabeled B12. The radioactive B12 absorbed from the gut would be excreted in the urine over 24 hours; the amount of urinary radioactivity reflected the patient's intrinsic absorptive capacity.

If urinary excretion was low, suggesting absorption defect, the test was repeated with intrinsic factor added to the oral dose. Normalization indicated pernicious anemia (intrinsic factor deficiency); persistent low excretion indicated ileal disease or bacterial overgrowth.

The Schilling test was retired in most clinical settings in the early 2000s because:

The modern replacements:

For most patients, the combination of clinical picture (macrocytic anemia, neurological symptoms, autoimmune background), elevated MMA, and positive anti-IF antibody is sufficient to confirm pernicious anemia without invasive testing.

Back to Table of Contents

Modern Diagnostic Workup

The recommended workup for suspected B12 deficiency anemia:

  1. Complete blood count (CBC) with differential and peripheral blood smear — assess hemoglobin, MCV, MCH, white cell count, platelet count, and morphology. Look for macrocytosis, oval macrocytes, hypersegmented neutrophils.
  2. Serum B12 — the starting point. <200 pg/mL is clearly deficient; 200-400 pg/mL is borderline; 400-900 pg/mL is normal; >900 pg/mL is supraphysiological (usually supplementation).
  3. Serum folate and red cell folate — rule out concurrent folate deficiency (which is also a cause of macrocytic anemia). Always check before starting folate supplementation.
  4. Methylmalonic acid (MMA) — the most specific functional marker of B12 deficiency. Elevated MMA in the presence of borderline or low B12 confirms functional deficiency.
  5. Homocysteine — elevated in B12 deficiency, but also elevated in folate deficiency, B6 deficiency, and renal insufficiency. Sensitive but not specific.
  6. Reticulocyte count — usually inappropriately low in megaloblastic anemia (because erythropoiesis is ineffective).
  7. LDH and indirect bilirubin — elevated due to intramedullary hemolysis (red cell precursors dying in the bone marrow).
  8. Iron studies — rule out concurrent iron deficiency, which can mask the macrocytosis of B12 deficiency.
  9. TSH — rule out hypothyroidism, which is commonly associated with PA and also causes macrocytosis.
  10. If B12 deficiency confirmed: anti-intrinsic factor antibodies, anti-parietal cell antibodies, and serum gastrin to evaluate for pernicious anemia.

The pattern that confirms B12 deficiency anemia: low or borderline B12, elevated MMA, elevated homocysteine, macrocytic anemia with hypersegmented neutrophils. Pernicious anemia is confirmed by positive anti-IF antibody and/or elevated gastrin with hypopepsinogenemia.

Back to Table of Contents

IM Injection Protocols

Intramuscular B12 injection has been the standard treatment for pernicious anemia and severe B12 deficiency for over 70 years. The British Society for Haematology and most US hematology consensus protocols use a version of the following:

Induction Phase (severe deficiency with neurological symptoms)

Induction Phase (no neurological symptoms, hematological only)

Continuation Phase

Maintenance Phase

Hydroxocobalamin is preferred over cyanocobalamin for maintenance in Europe because its longer tissue retention allows less frequent dosing (every 2-3 months vs monthly for cyanocobalamin). Hydroxocobalamin is now widely available in the US as well; ask the prescribing physician to specify the form.

Injection technique: deep IM into the deltoid or vastus lateralis. Most patients can be trained to self-inject after the induction phase, dramatically reducing the burden of treatment. Subcutaneous injection (less painful, easier to self-administer) has been shown to produce equivalent absorption in several recent studies and is now used in some practices.

Back to Table of Contents

High-Dose Oral (Berlin Protocol)

The single most important development in B12 medicine over the past 30 years is the demonstration that high-dose oral B12 (1000-2000 mcg/day) works even in pernicious anemia. This was first established systematically in the "Berlin protocol" and subsequent randomized trials.

The biological basis: although the great majority of dietary B12 absorption requires intrinsic factor and the ileal cubilin-amnionless receptor, a small fraction (1-2%) of any oral B12 dose can be absorbed by simple passive diffusion across the intestinal mucosa, distributed throughout the small intestine. The percentage is tiny but the absolute amount becomes clinically meaningful at high doses: 2% of 2000 mcg is 40 mcg/day, which substantially exceeds the daily requirement (2.4 mcg) and is sufficient to maintain physiological serum B12 levels indefinitely.

The Berlin protocol and its successors have established:

Practical Berlin-style protocol:

Adherence is the key issue with oral therapy — daily lifelong supplementation is harder to remember than a quarterly injection. For patients with reliable adherence, oral is more convenient, cheaper, and equally effective.

Back to Table of Contents

Response Monitoring

The hematological response to B12 repletion follows a predictable timeline:

If reticulocytosis does not occur within 10 days of starting parenteral B12, the diagnosis should be reconsidered. Failure to respond suggests:

Monitoring during maintenance: check serum B12, MMA, and CBC at 3 months, 6 months, then annually if stable. Patients on oral maintenance should have at least one repeat MMA at 6-12 months after switching to confirm continued adequacy.

Back to Table of Contents

Combined Iron + B12 + Folate Deficiency

One of the most clinically important presentations is combined deficiency: simultaneous iron, B12, and/or folate deficiency. This is particularly common in:

The hematological picture in combined deficiency can be confusing — iron deficiency causes microcytic anemia (low MCV), while B12/folate deficiency causes macrocytic anemia (high MCV). The two opposing effects can produce a normal-appearing MCV (the so-called "dimorphic" picture) that masks both deficiencies. Examination of the peripheral blood smear is critical: a dimorphic population of small hypochromic cells alongside large oval macrocytes is the giveaway.

Treatment requires addressing each deficiency separately:

Iron deficiency frequently coexists with B12 deficiency because both require gastric acid for proper absorption, and both rise in the same at-risk populations (elderly, post-gastrectomy, atrophic gastritis, vegan/vegetarian). Always check iron studies in any B12-deficient patient, and check B12 in any iron-deficient patient over age 50.

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Minot GR, Murphy WP (1934). Nobel Prize for the discovery that liver therapy cures pernicious anemia. — PubMed
  2. Kuzminski AM et al. (1998). Effective treatment of cobalamin deficiency with oral cobalamin. Blood. — the seminal trial showing oral B12 works in pernicious anemia. — PubMed
  3. Bolaman Z et al. (2003). Oral vs intramuscular cobalamin in megaloblastic anemia: a single-center, prospective, randomized trial. Clin Ther. — PubMed
  4. Vidal-Alaball J et al. (2005). Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. — PubMed
  5. Toh BH et al. (1997). Pernicious anemia. NEJM. — PubMed
  6. Lahner E, Annibale B (2009). Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol. — PubMed
  7. British Society for Haematology guidelines on cobalamin and folate deficiency (Devalia 2014). — PubMed
  8. Annibale B et al. (1999). Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter. — PubMed
  9. Carmel R (2008). How I treat cobalamin (vitamin B12) deficiency. Blood. — PubMed
  10. Hvas AM, Nexo E (2006). Diagnosis and treatment of vitamin B12 deficiency — an update. Haematologica. — PubMed
  11. Stabler SP (2013). Vitamin B12 deficiency. NEJM. — PubMed
  12. Sun AL et al. (2018). Risk of gastric cancer in pernicious anemia: a meta-analysis. Eur J Cancer Prev. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents